Clinical Trials Browser

Phase 2 × Withdrawn × farletuzumab × Clear all

NCT01203618 2013-11-04

Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas

Phase 2 Withdrawn

Pituitary Neoplasms